Efficacy and tolerability of novel triple combination therapy in drug-na챦ve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial by �씠�슜�샇
1Kim NH, et al. BMJ Open 2018;8:e022448. doi:10.1136/bmjopen-2018-022448
Open access 
Efficacy and tolerability of novel triple 
combination therapy in drug-naïve 
patients with type 2 diabetes from the 
TRIPLE-AXEL trial: protocol for an 
open-label randomised controlled trial
Nam Hoon Kim,1 Soo Lim,2,3 Soo Heon Kwak,3 Min Kyong Moon,3,4 
Jun Sung Moon,5 Yong-ho Lee,6 Ho Chan Cho,7 Juneyoung Lee,8 Sin Gon Kim1
To cite: Kim NH, Lim S, 
Kwak SH, et al.  Efficacy 
and tolerability of novel 
triple combination therapy 
in drug-naïve patients with 
type 2 diabetes from the 
TRIPLE-AXEL trial: protocol 
for an open-label randomised 
controlled trial. BMJ Open 
2018;8:e022448. doi:10.1136/
bmjopen-2018-022448
 ► Prepublication history for 
this paper is available online. 
To view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
022448).
Received 21 February 2018
Revised 5 June 2018
Accepted 2 August 2018
For numbered affiliations see 
end of article.
Correspondence to
Dr Sin Gon Kim;  
 k50367@ korea. ac. kr
Protocol
© Author(s) (or their 
employer(s)) 2018. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Introduction Patients with type 2 diabetes are at risk 
of microvascular and macrovascular complications. 
Intensive glycaemic control, especially in patients with 
short duration of diabetes, is the mainstay of management 
of type 2 diabetes to lower the risk of complications. 
However, despite the improvement in the understanding of 
the pathophysiology of type 2 diabetes and development 
of novel glucose-lowering agents, long-term durable 
glycaemic control remains a difficult goal to achieve. Several 
challenging clinical trials proved that an early combination 
therapy with a variety of glucose-lowering agents had a 
more favourable effect than conventional stepwise therapy 
in terms of glycaemic control. We aim to evaluate the 
efficacy and tolerability of a novel, initial triple combination 
therapy with metformin, sodium glucose cotransporter 2 
inhibitor (dapagliflozin) and dipeptidyl peptidase-4 inhibitor 
(saxagliptin) compared with conventional stepwise add-on 
therapy in drug-naïve patients with recent-onset type 2 
diabetes.
Methods and analysis This study is a multicentre, 
prospective, randomised, open-label, parallel group, 
comparator-controlled trial. A total of 104 eligible participants 
will be randomised to either the initial combination therapy 
group or the conventional stepwise add-on therapy group 
for 104 weeks. The primary endpoint is the proportion of 
patients who achieved haemoglobin A1c level<6.5% without 
hypoglycaemia, weight gain or discontinuation due to 
adverse events at 104 weeks. This trial will determine 
whether a novel triple combination therapy with metformin, 
dapagliflozin and saxagliptin has a beneficial effect on 
durable glycaemic control compared with conventional 
therapy in drug-naïve patients with type 2 diabetes.
Ethics and dissemination This study protocol was 
approved by the local institutional review boards and 
independent ethics committees over the recruitment sites. 
Results of this study will be disseminated in scientific 
journals and scientific conferences.
trial registration number NCT02946632; Pre-results.
IntroduCtIon
Type 2 diabetes is a metabolic disorder char-
acterised by hyperglycaemia and increased 
risk for microvascular and macrovascular 
complications.1 2 Landmark clinical trials in 
the management of type 2 diabetes including 
the United Kingdom Prospective Diabetes 
Study (UKPDS), Action to Control Cardio-
vascular Risk in Diabetes Study, Action in 
Diabetes and Vascular Disease: Preterax and 
Diamicron MR Controlled Evaluation and 
Veterans Affairs Diabetes Trial have shown 
that intensive glycaemic control reduced the 
risk for microvascular complications.3–6 In 
addition, intensive glycaemic control in the 
early period of diabetes progression was asso-
ciated with a significantly lower incidence of 
cardiovascular disease and mortality.7 Based 
on the data from these trials, many interna-
tional and local clinical guidelines proposed 
the glycaemic targets as haemoglobin A1c 
(HbA1c) level<7.0% in general, and a more 
stringent target (6.0%–6.5%) in patients 
whose duration of diabetes was shorter, free 
from vascular complications or who were 
young.8–11 
However, progressive β-cell failure and 
clinical inertia have limited long-term 
durable glycaemic control in patients with 
type 2 diabetes.12 In the post-hoc analysis in 
the UKPDS, over 70% of patients who were 
treated with sulfonylurea or insulin eventu-
ally failed to achieve the target HbA1c level 
strengths and limitations of this study
 ► This long-term, multicentre, randomised controlled 
trial will provide novel concept of early intensive 
treatment with triple glucose-lowering agents com-
bination in patients with type 2 diabetes.
 ► Lack of blinding due to open-label concept.
 ► Long-term treatment period may limit the complete 
retention of participants.
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(<7.0%) over 9 years.13 Treatment with thiazolidinedi-
ones or some sodium glucose cotransporter 2 (SGLT-2) 
inhibitors has shown a more favourable effect on durable 
glycaemic control than sulfonylurea; however, this also 
could not achieve long-term sustainable results.14 15 This 
evidence consistently suggested the limited ability to 
sustain favourable glycaemic control with monotherapy, 
irrespective of the drugs used.
Therefore, some challenging trials focused on the early 
intensive therapy as an alternative option for managing 
hyperglycaemia in type 2 diabetes. Intensive insulin 
therapy targeting near normal range of glycaemia in 
patients with recent-onset type 2 diabetes had promising 
results, even long-term resolution of diabetes.16 17 On the 
other hand, early combination therapy with two different 
classes of glucose-lowering agents also had favourable 
glycaemic control. For example, a dual add-on with SGLT-2 
inhibitor plus dipeptidyl peptidase-4 (DPP-4) inhibitor 
to the patients who failed with metformin monotherapy 
has shown greater improvement in glycaemic control 
than single add-on with each drug.18 19 Recently, a more 
challenging trial evaluated the initial triple combination 
therapy in drug-naïve patients with type 2 diabetes.20 
The initial combination with metformin, pioglitazone 
and exenatide has shown significantly better long-term 
glycaemic control than stepwise therapy.
Therefore, we focused on a different triple combina-
tion for safe and efficient glycaemic control: metformin, 
SGLT-2 inhibitor and DPP-4 inhibitor. An SGLT-2 inhib-
itor, dapagliflozin, lowers hyperglycaemia via blocking 
SGLT-2 to increase glucosuria, that is, in an insulin-in-
dependent manner.21 22 A DPP-4 inhibitor, saxagliptin, 
increases the serum level of Glucagon-like peptide-1 (GLP-
1), and potentiates its action of increasing glucose-depen-
dent insulin secretion and lowering glucagon secretion.23 
Therefore, the mechanism of action of these drugs is 
complementary to that of metformin, and all of these have 
a low risk of hypoglycaemia and weight gain, suggesting 
safe and powerful combination regimen.
Based on these backgrounds, we designed a randomised 
controlled trial to assess the efficacy and tolerability of a 
novel, initial triple combination therapy with metformin, 
saxagliptin and dapagliflozin, compared with conven-
tional stepwise add-on therapy with metformin, followed 
by glimepiride, and sitagliptin in drug-naïve patients with 
recent-onset type 2 diabetes (the TRIPLE-AXEL study).
MEthods
study design and overview
The TRIPLE-AXEL study is an investigator-initiated, 
prospective, randomised, open-label, parallel group, 
comparator-controlled trial. The eligible patients will be 
recruited from seven tertiary medical centres in South 
Korea, according to inclusion and exclusion criteria 
(box 1). After initial screening, patients will be randomised 
to the initial triple combination therapy group or the 
conventional stepwise add-on therapy group and followed 
up to the end of the study (104 weeks). The overall scheme 
of the study is described in figure 1.
At the first visit after randomisation, baseline data 
including participants’ vital signs, anthropometric 
measures, electrocardiography and laboratory data will 
be collected according to the protocol. The participants 
assigned to the initial triple combination therapy group 
will take two tablets of the study drugs one time a day, and 
those assigned to the conventional stepwise therapy group 
will take medications sequentially according to a predeter-
mined order based on their baseline HbA1c levels (details 
are described in the following section). Participants will 
undergo a blood test for glycaemic markers at each visit 
to adjust the medication doses or regimens. At each visit, 
investigators will check the participants’ medical condi-
tions, vital signs and any adverse events (AEs) related to 
medications including hypoglycaemic events.
Enrolment and randomisation
Eligible participants at screening who meet the inclusion 
criteria will be randomly assigned to either the triple 
combination therapy group or the conventional stepwise 
therapy group. Randomisation codes will be generated 
in blocks to ensure approximate balance (1:1) between 
the two treatment arms using a stratified block randomis-
ation. Eligible subjects will be randomised within 2 weeks 
after the screening visit. The randomisation code will be 
sequentially generated within each centre as well as based 
on subject’s initial level of HbA1c (<9% versus≥9%). Once 
a block of randomisation codes is exhausted, the next 
box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► Drug-naïve patients with type 2 diabetes diagnosed by American 
Diabetes Association criteria.
 ► Haemoglobin A1c level ≥8%, <10.5% at screening.
 ► Age≥18 years,<65 years.
 ► Body mass index≥23 kg/m2,<35 kg/m2.
 ► Estimated glomerular filtration rate≥60 mL/min/1.73 m2.
Exclusion criteria
 ► Uncontrolled hyperglycaemia >270 mg/dL after an overnight fast.
 ► Diabetic ketoacidosis.
 ► Type 1 diabetes.
 ► Confirmed cardiovascular disease (acute coronary syndrome, stroke 
or transient ischaemic attack) within 3 months of screening.
 ► Congestive heart failure (New York Heart Association functional 
class III or IV).
 ► Severe hepatic dysfunction (serum levels of either aspartate ami-
notransferase, alanine aminotransferase or alkaline phosphatase 
above three times upper limit of normal.
 ► Alcohol abuse within 3 months prior to informed consent that would 
interfere with trial participation or any ongoing condition leading to 
a decreased compliance to study procedures or study drug intake.
 ► Pregnant women, women with potential of pregnancy not using 
adequate contraception method as evaluated by the investigator, 
lactating women.
 ► Use of systemic glucocorticoid.
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available block will be used within each stratum. For each 
randomised subject, the envelope will provide the inves-
tigator with a unique randomisation number matching 
the treatment arm assigned to the subject. Following 
randomisation, the assigned therapy will be applied to 
the subject as soon as possible.
study procedures
Initial triple combination group
Participants in the initial combination therapy group will 
be started on Xigduo (metformin 1000 mg plus dapagli-
flozin 10 mg combination), saxagliptin 5 mg one time a 
day before breakfast, maintained for 104 weeks. At any 
visits, if participants have gastrointestinal discomfort 
probably due to metformin, dose reduction (metformin 
in Xigduo to 500 mg) is possible based on physicians’ 
decision. If patients are still intolerable to the lower dose 
of metformin, it should be discontinued and recorded as 
an AE.
Conventional stepwise therapy group
Participants in the conventional stepwise therapy group 
will be further stratified to two different procedure regi-
mens according to the baseline level of HbA1c. First, if 
participants’ baseline HbA1c level≥8.0%, and<9.0%, 
they will be started on metformin 1000 mg one time 
a day before breakfast. At each visit, fasting plasma 
glucose (FPG) and HbA1c levels will be measured, and 
the sequential add-on therapy will be held according to 
the regimen described in table 1. Second, if participants’ 
baseline HbA1c level≥9.0%, and <10.5%, they will be 
started on metformin 1000 mg one time a day plus glime-
piride 2 mg one time a day before breakfast. The subse-
quent add-on regimen is described in table 2. At any visit, 
if severe or recurrent hypoglycaemia is observed, step 
down is possible based on physicians’ decision. Similar 
to the initial triple combination groups, if patients have 
gastrointestinal discomfort probably due to metformin, 
dose reduction (to 500 mg metformin) is possible based 
on physicians’ decision.
Rescue therapy
Open-label rescue medications including insulin except 
metformin, GLP-1 receptor agonist, other DPP-4 inhibi-
tors and other SGLT-2 inhibitors can be given to partici-
pants with FPG>270 mg/dL (week 4–12), or FPG>240 mg/
dL (week 12–26), or FPG>200 mg/dL (week 26–104).
Endpoints
Primary endpoint
The primary objective of this study is to determine the 
efficacy and tolerability of the initial triple combination 
therapy with metformin, dapagliflozin and saxagliptin 
compared with conventional stepwise add-on therapy 
Figure 1 Overall study design. BMI, body mass index; HbA1c, haemoglobin A1c; T2DM, type 2 diabetes mellitus.
Table 1 Sequential add-on therapy regimen in the conventional treatment group (baseline haemoglobin A1c (HbA1c) 
level≥8.0%, <9.0%)
Order Regimen
The first add-on if FPG level≥120 mg/dL, metformin is increased to 2000 mg (1000 mg two times a day
The second add-on if FPG level≥120 mg/dL, or HbA1c level≥6.5%, glimepiride 1 mg or 2 mg/day is started before breakfast
The third add-on if FPG level≥120 mg/dL, or HbA1c level≥6.5%, glimepiride is increased to 4 mg/day maximally (based on 
physician’ s decision)
The fourth add-on if FPG level≥120 mg/dL, or HbA1c level≥6.5%, sitagliptin 100 mg/day is added
*if FPG level<120 mg/dL, or HbA1c level<6.5% at each visit, the previous regimen is maintained. At any 
visit, if severe or recurrent hypoglycaemia, step down is possible based on physician’s decision. At any 
visit, if patients have gastrointestinal discomfort probably due to metformin, dose reduction (to 500 mg 
as metformin) is possible based on physician’s decision. If patients still intolerable to lower dose of 
metformin, it should be discontinued and recorded as adverse events.
FPG, fasting plasma glucose.
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with metformin and/or sulfonylurea and/or sitagliptin 
in drug-naïve patients with type 2 diabetes. Therefore, we 
set the primary endpoint as the proportion of patients 
who achieved HbA1c level<6.5% without hypoglycaemia, 
weight gain or discontinuation due to AEs at 104 weeks. 
Weight gain is defined as gaining body weight≥5% of 
initial body weight.
Secondary endpoints
 ► Proportion of patients who achieved HbA1c 
level<6.5% without hypoglycaemia, weight gain or 
discontinuation due to AEs at 56 weeks.
 ► Time to reach target HbA1c level (<6.5%).
 ► Change in HbA1c level from baseline to week 56 and 
104.
 ► Change in FPG from baseline to week 56 and 104.
 ► Proportion of patients who achieve HbA1c 
level<7.0% without hypoglycaemia, weight gain or 
discontinuation due to AEs at 56 and 104 weeks.
 ► Change in body weight from baseline to week 56 and 
104.
 ► Change in systolic blood pressure from baseline to 
week 56 and 104.
 ► Changes in fat and lean mass at 56 and 104 weeks.
safety
An AE is defined as any untoward medical occurrence (any 
unfavourable and unintended sign, symptom or disease) 
in a study participant. AEs of special interests are hypogly-
caemia, gastrointestinal trouble, urinary tract infection, 
genital tract infection, volume depletion, pancreatitis, 
severe cutaneous events and hypersensitivity reactions. 
Any type of hypoglycaemia will be recorded at each visit. 
Each hypoglycaemic event will be defined based on the 
five criteria suggested by the American Diabetes Associa-
tion (ADA) Workgroup on Hypoglycaemia: severe hypo-
glycaemia, documented symptomatic hypoglycaemia, 
asymptomatic hypoglycaemia, probable symptomatic 
hypoglycaemia and relative hypoglycaemia.24 Among 
these, severe or confirmed hypoglycaemia will be applied 
to the adjudication of the primary outcome.
At each visit during the whole study period, any AEs 
will be recorded by investigators. The intensity of AEs will 
be judged as mild, moderate or severe according to the 
frequency, duration and tolerability of the signs or symp-
toms. The medical judgement also will be used to deter-
mine the relationship considering all relevant factors.
stAtIstICAl AnAlysEs
sample size calculation
The tolerability will be measured using a composite endpoint 
with no hypoglycaemia, no weight gain or discontinuation 
due to a safety concern. It is assumed that the initial triple 
combination therapy will show a total of at most 10% intol-
erability (5% for hypoglycaemia, 0% for weight gaining 
or 5% for discontinuation due to AEs), while the stepwise 
add-on therapy will show a total of at most 70% intolera-
bility (20% for hypoglycaemia, 30% for weight gaining or 
20% for discontinuation due to AEs). A total of 10 subjects 
per group provided 90% power to detect a difference of 
60% tolerability decrease (90% vs 30%) for the initial triple 
combination therapy compared with the stepwise add-on 
therapy with a two-sided 5% level of significance.
To compare the efficacy of therapies, we assume that 
half of the subjects who are tolerable to the therapies will 
reach the target HbA1c level. A total of 46 subjects per 
group, then, are needed to provide 90% power in order 
to detect a 30% (45% vs 15%) increase in HbA1c target 
goal achievement rate of the initial triple combination 
therapy compared with the stepwise add-on therapy with 
a two-sided 5% level of significance based on normal 
approximation with unpooled variance.
Assuming that about 10% of subjects would be lost 
to follow-up during study periods, we aim to recruit 52 
subjects per group (104 subjects in total) for this study.
statistical methods and analysis
Statistical analyses will be performed in accordance with the 
study protocol. For data summaries, continuous variables 
will be summarised using the mean, SD, median, IQR (the 
first and third quartiles) and range (the minimum and 
maximum values). Categorical variables will be summarised 
using frequency counts and percentages. Data will be 
summarised by treatment group and overall.
The primary analysis population will be the full analysis 
set (FAS) and supportive analyses using the per-protocol 
Table 2 Sequential add-on therapy regimen in the conventional treatment group (baseline haemoglobin A1c (HbA1c) 
level≥9.0%, <10.5%)
Order Regimen
The first add-on if FPG level≥120 mg/dL, metformin is increased to 2000 mg (1000 mg two times a day) and glimepiride 
is increased to 4 mg (2 mg two times a day)
The second add-on if FPG level≥120 mg/dL, or HbA1c level≥6.5%, sitagliptin 100 mg/day is added
*if FPG level<120 mg/dL, or HbA1c level<6.5% at each visit, the previous regimen is maintained. At any 
visit, if severe or recurrent hypoglycaemia, step down is possible based on physician’s decision. At any 
visit, if patients have gastrointestinal discomfort probably due to metformin, dose reduction (to 500 mg 
as metformin) is possible based on physician’s decision. If patients still intolerable to lower dose of 
metformin, it should be discontinued and recorded as adverse events.
FPG, fasting plasma glucose.
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set (PPS) will also be performed. The primary efficacy 
endpoint, the proportion of subjects who achieve HbA1c 
level<6.5% without hypoglycaemia, weight gain or discon-
tinuation due to AEs at 104 weeks, between the initial 
triple combination therapy and the conventional step-
wise add-on therapy will be analysed using Pearson’s Χ2 
test without imputing any missing values of HbA1c at 
104 weeks. If any variable of the baseline characteristics 
differs between groups, a generalised estimating equation 
(GEE) analysis will be performed to adjust its difference.
For secondary variables, changes from the baseline will 
be compared between groups by Student’s t-test using the 
difference of the values from baseline to week 56 and 104 
for the FAS and PPS. Changes from baseline to week 56 
and 104 through all visits will be analysed using GEE anal-
ysis for both FAS and PPS. The outcome variable will be 
the change from baseline. The proportion of patients who 
achieve HbA1c level<7.0% without hypoglycaemia, weight 
gain or discontinuation due to AEs at 56 and 104 weeks will 
be analysed using the same method as the primary efficacy 
analysis. Time to reach target HbA1c level (<6.5%) will be 
summarised using Kaplan-Meier survival curves for each 
group, and will be compared using log-rank test between 
groups. A multivariable analysis with Cox’s proportional 
hazard regression model will also be performed, if neces-
sary. Specifically, baseline covariates showing significant 
difference with p<0.05 as well as those discreetly chosen by 
clinical judgement will be adjusted as potential confounders 
in the multivariable model.
Statistical significance will be assessed based on 
two-sided 5% level of significance, and all statistical anal-
yses will be performed using Statistical Analysis System 
(SAS) software, V.9.3 (SAS Institute).
Patient and public involvement
Patients and public were not actively involved in the 
research question and protocol development including 
outcome measures. The participants will be provided 
information of the final study results by the clinical 
research information service.
dIsCussIon
The study is designed to compare the effects of two 
different medication regimens on long-term glycaemic 
control in type 2 diabetes: metformin plus dapagliflozin 
plus saxagliptin versus metformin, followed by glime-
piride, and sitagliptin. In addition, it also compares the 
efficacy of an early intensive therapy versus a conven-
tional stepwise therapy.
Many clinical guidelines for the management of type 
2 diabetes, including ADA/European Association for the 
Study of Diabetes guideline, and Korean Diabetes Asso-
ciation guideline recommend stepwise add-on therapy 
from a single agent (usually metformin) to a combina-
tion of second and third glucose-lowering agents.10 11 It is 
based on large amount of evidence including numerous 
randomised controlled trials, and economic rationality. 
However, for a long-term treatment period, most patients 
with type 2 diabetes have failed to sustain favourable 
glycaemic control with monotherapy, and even dual or 
triple combination therapy, eventually requiring insulin 
therapy. Remarkable advances in the understanding of 
the pathophysiology of type 2 diabetes and development 
of novel glucose-lowering agents have made it possible 
to apply a variety of therapeutic options to patients with 
type 2 diabetes. However, we still do not have any perfect 
strategy for the management of hyperglycaemia. It is 
regarded as mainly due to the progressive β-cell failure 
in the natural course of type 2 diabetes, and the absence 
of clear therapeutics preserving β-cell secretory func-
tion.25–27 As mentioned above, the early intensive insulin 
therapy showed a potential to preserve β-cell function 
in a specific clinical setting. In drug-naïve patients with 
type 2 diabetes, early short-term intensive insulin therapy 
with continuous insulin infusion in a hospitalised setting 
induced long-term favourable glycaemic control, and this 
was associated with improvement of first-phase insulin 
secretion.17 Similar results were reproduced in a large-
scale randomised trial comparing the effects of tran-
sient intensive insulin therapy versus oral hypoglycaemic 
agents on long-term glycaemic control.16 In that study, 
Homeostatic model assessment (HOMA)-β and acute 
insulin response also improved significantly after inten-
sive insulin therapy, implying that intensive interventions 
that reduce glucotoxicity would be an effective strategy 
for long-term sustainable glycaemic control especially in 
an early phase of type 2 diabetes.
However, it is difficult to apply the same insulin regimen 
to all drug-naïve patients in a routine clinical setting 
although it ensures promising results. Insulin therapy, 
with multiple daily injections or continuous insulin infu-
sion, has psychological and practical barriers to both 
patients and clinicians. In addition, hypoglycaemia or 
weight gain is inevitable with those regimens. There-
fore, we need more practical and safe options for early 
intensive therapies, and this study will demonstrate the 
potential benefit of an early triple combination therapy 
in patients with type 2 diabetes. From the results of oral 
glucose tolerance test before and after the trial, we will be 
able to identify changes in the insulin secretory functions 
and insulin resistance after each treatment.
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